What Is Rein Therapeutics, Inc. (RNTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Rein Therapeutics, Inc.'s intrinsic value is estimated at a composite fair value of $0.59. Trading at $0.95, the stock is approaching fair value or slight overvaluation (implied return of -37.3%), as 5 of 7 models suggest limited further upside. Model dispersion is worth noting: ML-RIV targets $1.04 (+9.6%), versus Bayesian DCF at $0.03 (-96.7%). This +106.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About RNTX?
7 of 13 models are currently active for RNTX. Of these, 1 model suggests upside while 6 models suggest overvaluation. The Bayesian DCF estimates RNTX's intrinsic value at $0.03, implying -96.7% downside from the current price. See which stocks rank higher →
How Does RNTX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, RNTX ranks #380 by Quality of Company score. CirclFi's QOC score of 3.3/10 evaluates 32 fundamental signals. A score of 3.3 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Rein Therapeutics, Inc.'s positioning within the Pharmaceutical Preparations segment means that biosimilar competition timeline plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.
Is RNTX a Value Trap?
CirclFi's Value Trap algorithm assigns RNTX a score of 41/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Rein Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Rein Therapeutics, Inc. earns a quality score of 3.3/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.
The gap between the most bullish and bearish model spans +106.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RNTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RNTX's 7 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad